These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24821316)

  • 1. A drug safety evaluation of rituximab and risk of hepatitis B.
    Riedell P; Carson KR
    Expert Opin Drug Saf; 2014 Jul; 13(7):977-87. PubMed ID: 24821316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
    Zhang B; Wang J; Xu W; Wang L; Ni W
    Onkologie; 2010; 33(10):537-9. PubMed ID: 20926902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
    Viganò M; Mangia G; Lampertico P
    Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab.
    Buensalido JA; Chandrasekar PH
    Expert Rev Anti Infect Ther; 2014 Feb; 12(2):151-4. PubMed ID: 24341369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
    Liu CY; Chandrasekar PH; Masood A; Schiffer CA
    J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
    Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
    Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
    Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
    J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
    Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?
    Kusumoto S; Tanaka Y; Mizokami M; Ueda R
    J Clin Oncol; 2013 Dec; 31(35):4480. PubMed ID: 24220561
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
    Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
    Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B reactivation and timing for prophylaxis.
    Tuna N; Karabay O
    World J Gastroenterol; 2015 Feb; 21(7):2263-4. PubMed ID: 25717269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of hepatitis B virus with rituximab.
    Tsutsumi Y; Kanamori H; Mori A; Tanaka J; Asaka M; Imamura M; Masauzi N
    Expert Opin Drug Saf; 2005 May; 4(3):599-608. PubMed ID: 15934864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation.
    Martin ST; Cardwell SM; Nailor MD; Gabardi S
    Am J Transplant; 2014 Apr; 14(4):788-96. PubMed ID: 24592928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
    Papamichalis P; Alexiou A; Boulbou M; Dalekos GN; Rigopoulou EI
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):84-93. PubMed ID: 21920838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.